Browse
Browse
Home
People
Organizations
Research
Events
Capability Map
Grant
RDF
pages:
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
more...
A Trial to Improve Surrogate Decision-Making for Critically III Older Adults
A Two-Part Multicenter Prospective Longitudinal Study of CFTR-Dependent Disease Profiling in Cystic Fibrosis (PROSPECT)
A Two-Part Multicenter Prospective Longitudinal Study of CFTR-Dependent Disease Profiling in Cystic Fibrosis (PROSPECT) ("Clinical Study")
A Website to Teach Children Safety with Dogs: Development and Evaluation
A Whole-Epigenome Approach to Identifying Novel Targets for Nano-Pharm Memory Enhancement
A-Z Clinical Trials Unit
A20 Promotes Glioma Stem Cell Mediated Tumorigenesis
A5210.04-University of Alabama at Birmingham - VSL 54
A5272/A5280 Supplemental Funds from Adult Clinical Trials Group
A5391- Doravirine for Persons with Excessive Weight Gain on Integrase Inhibitors and Tenofovir Alafenamide (The Do IT Study)
AAAS Fellowship
AADR Proctor & Gamble Underrepresented Faculty Research Fellowship
AADR-Anne D. Haffajee Fellowship
AADVL18P1 – An Open-Label Feasibility Study to Assess the Safety and Pharmacokinetics of Enasidenib in Pediatric Patients with Relapsed/Refractory Acute Myeloid Leukemia R/R-AML with an Isocitrate Dehydrogenase-2 IDH2 Mutation”,
AAHPM Y.C. Ho/Helen & Michael Chiang Foundation 2016 Fellowship Grant
AALL 1521; A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib with Chemotherapy in Children with De Novo High-Risk CRLF2- Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Lukemia
AALL0434-Novartis Pharmaceuticals Corporation
AALL1131 Supplemental PCR
AALL1331: Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND#100135, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
AALL1621- A Phase 2 Study of Inotuzumab Ozogamicin (NSC#772518, IND#133494) in Children and Young Adults with Relapsed or Refractory CD22+B-Acute Lymphoblastic Leukemia(B-ALL)
AALL1721 - A Single Arm Phase II Trial to Assess the Efficacy and Safety of CTL019 in First Line High-Risk (HR) Pediatric and Young Adult Patients with B-Cell Acute Lymphoblastic Leukemia (B- ALL) Who are Minimal Residual Disease (MRD) Positive at the End of Consolidation (EOC) Therapy
AALL1931 - An Open-Label, Multicenter Study of RC-P in Patients with Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL) Following Hypersensitivity to E. Coll-Derived Asparaginases
AAML 1031 - A Phase III Randomized Trial for Patients with De Novo AML Using Bortezomib (NSC# 681239) and Sorafenib (BAY 43-9006, NSC# 724772) for Patients with High Allelic Ratio FLT2/ITD
AAML 1031 - Bayer
AAML1031: One Time EOY, Integrated BIQSFP AAML1031-Echocardiogram Reports and Images
AANP Neurodegenerative Disease Scholars Program
AAP School Nurse and Pediatrician Learning Collaborative
AAV-Based Plasmacytoid Dentritic Cell Cancer Vaccine
AAV-Mediated Gene Therapy for Metabolic Bone Disease
Abbott Fund Interventional Fellowship Grant 2017-2018
pages:
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
more...